Literature DB >> 8739341

The effect of the combination therapy with sucralfate and famotidine on experimentally induced duodenal ulcers in rats.

P Zupancic1.   

Abstract

The combination of sucralfate (SUC) and famotidine (FAM) at subtherapeutic dose on cysteamine-induced duodenal ulcers (3 x 250 mg/kg) in female rats was studied. Subtherapeutic doses were determined in the preliminary studies. They were 200 mg/kg SUC and 0.2 mg/kg FAM (twice a day). The macroscopic examination was done 24 hours after first application of cysteamine. The effectiveness of SUC and FAM combination in subtherapeutic doses was confirmed by decreased number (from 1.3 to 0.5), length (from 5.5 mm to 1.9 mm), severity of duodenal ulcers (from 3.4 to 1.2) and reduction of ulcerative index by 54.4%.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739341

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  5 in total

Review 1.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 2.  Experimental production of duodenal ulcers.

Authors:  A Robert
Journal:  Biol Gastroenterol (Paris)       Date:  1974 Apr-May

3.  Pathogenesis of duodenal ulceration produced by cysteamine or propionitrile: influence of vagotomy, sympathectomy, histamine depletion, H-2 receptor antagonists and hormones.

Authors:  S Szabo; L R Haith; E S Reynolds
Journal:  Dig Dis Sci       Date:  1979-06       Impact factor: 3.199

4.  Prevention of duodenal ulcers in the rat using a combination of ranitidine and sucralphate in subtherapeutic doses.

Authors:  S Bank; H Zimmerman; C Smolow; V Kranz
Journal:  Gut       Date:  1985-06       Impact factor: 23.059

5.  Development and characteristics of sucralfate.

Authors:  R Nagashima
Journal:  J Clin Gastroenterol       Date:  1981       Impact factor: 3.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.